This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Efficacy

Authoring team

The proportion of patients who respond to tamoxifen depends on the characteristics of the tumour:

  • 30% of all patients with breast cancer respond to tamoxifen
  • 50% of patients with tumours which express the oestrogen receptor will respond
  • 15% of patients with tumours which do not express the oestrogen receptor will respond

The efficacy of treatment varies with respect to pre- and post- menopausal women.

  • pre-menopausal adjuvant therapy with tamoxifen - results in a 12% reduction in annual risk of recurrence and 6% reduction in mortality.
  • post-menopausal adjuvant therapy with tamoxifen - results in a 29% reduction in annual risk of recurrence and a 20% reduction in annual risk of mortality.

Bulbrook (BMJ editorial, 1996) suggests that more than five years' adjuvant therapy is not warranted because continuation of tamoxifen treatment would be unlikely to result in clinical benefit.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.